BioMérieux Overview
- Year Founded
-
1963
- Status
-
Public
- Employees
-
15,226
- Stock Symbol
-
BIM
- Investments
-
61
- Share Price
-
$102.54
- (As of Friday Closing)
BioMérieux General Information
Description
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.
Contact Information
Website
www.biomerieux.comCorporate Office
- 376 Chemin de l'Orme
- 100 allée Louis Pasteur
- 69280 Marcy-l'Etoile
- France
Corporate Office
- 376 Chemin de l'Orme
- 100 allée Louis Pasteur
- 69280 Marcy-l'Etoile
- France
BioMérieux Stock Performance
As of 13-Nov-2026, BioMérieux’s stock price is $102.54. Its current market cap is $12.1B with 118M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $102.54 | $102.40 | $74.96 - $136.01 | $12.1B | 118M | 167K | $4.58 |
BioMérieux Financials Summary
As of 30-Jun-2026, BioMérieux has a trailing 12-month revenue of $4.66B.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 9,133,825 | 15,449,542 | 13,011,611 | 13,240,766 |
| Revenue | 4,655,118 | 4,590,759 | 4,306,645 | 3,976,194 |
| EBITDA | 915,252 | 956,436 | 970,643 | 769,464 |
| Net Income | 539,633 | 448,382 | 467,683 | 386,950 |
| Total Assets | 6,501,399 | 6,548,148 | 6,004,100 | 5,813,519 |
| Total Debt | 481,644 | 541,969 | 510,088 | 573,592 |
BioMérieux Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
BioMérieux Comparisons
Industry
Financing
Details
BioMérieux Competitors (14)
One of BioMérieux’s 14 competitors is Bio-Rad Laboratories, a Corporation company based in Hercules, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Bio-Rad Laboratories | Corporation | Hercules, CA | ||||
| GSK | Corporation | London, United Kingdom | ||||
| Hologic | Private Equity-Backed | Marlborough, MA | ||||
| Sartorius | Corporation | Goettingen, Germany | ||||
| Novartis | Corporation | Basel, Switzerland |
BioMérieux Patents
BioMérieux Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| FR-3174570-A1 | Analysis support including a chip and a chip | Pending | 25-Apr-2025 | ||
| WO-2026224444-A1 | Array substrate comprising a chip, and chip | Pending | 25-Apr-2025 | ||
| WO-2026171756-A1 | Dna/rna-dependent fluorescent compounds, and uses thereof | Pending | 13-Feb-2025 | ||
| EP-4793322-A1 | Fluorescent dna/rna-dependent compounds and uses thereof | Pending | 13-Feb-2025 | ||
| WO-2026125835-A1 | Capsule and method for compartmentalizing extraction particles in a container | Pending | 13-Dec-2024 | B01J13/02 |
BioMérieux Signals
BioMérieux Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
BioMérieux Investments & Acquisitions (61)
BioMérieux’s most recent deal was a Later Stage VC with Plair (Medical devices) for . The deal was made on 27-Mar-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Plair (Medical devices) | 27-Mar-2026 | Later Stage VC | Monitoring Equipment | ||
| Accellix | 22-Jan-2026 | Merger/Acquisition | Diagnostic Equipment | ||
| Allergen Alert | 14-Oct-2025 | Early Stage VC | Information Services (B2C) | ||
| Suzhou Hybiome Biomedical Engineering | 31-Jul-2025 | Secondary Transaction - Private | Diagnostic Equipment | ||
| Day Zero Diagnostics | 13-Jun-2025 | Merger/Acquisition | Diagnostic Equipment |
BioMérieux ESG
Risk Overview
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Healthcare
Industry
Rank
Percentile
Medical Devices
Subindustry
Rank
Percentile
BioMérieux Exits (13)
BioMérieux’s most recent exit was on 17-Jan-2023 from InDevR. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| InDevR | 17-Jan-2023 | Completed |
|
||
| Qvella | 04-Dec-2017 | Completed |
|
||
| Knome (US) | 21-Jan-2014 | Completed |
|
||
| Quanterix | 15-Nov-2012 | Completed |
|
||
| Knome (US) | 01-Aug-2011 | Early Stage VC | Completed |
BioMérieux Affiliates
Subsidiaries (15)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Lumed | Sherbrooke, Canada | 2012 | |
| Neoprospecta | Florianopolis, Brazil | 2011 | |
| Suzhou Hybiome Biomedical Engineering | Suzhou, China | 2009 | |
| Accellix | San Jose, CA | 2007 | |
| Ceeram | La Chapelle-sur-Erdre, France | 2005 |
BioMérieux FAQs
-
When was BioMérieux founded?
BioMérieux was founded in 1963.
-
Where is BioMérieux headquartered?
BioMérieux is headquartered in Marcy-l'Etoile, France.
-
What is the size of BioMérieux?
BioMérieux has 15,226 total employees.
-
What industry is BioMérieux in?
BioMérieux’s primary industry is Diagnostic Equipment.
-
Is BioMérieux a private or public company?
BioMérieux is a Public company.
-
What is BioMérieux’s stock symbol?
The ticker symbol for BioMérieux is BIM.
-
What is the current stock price of BioMérieux?
As of 13-Nov-2026 the stock price of BioMérieux is $102.54.
-
What is the current market cap of BioMérieux?
The current market capitalization of BioMérieux is $12.1B.
-
What is BioMérieux’s current revenue?
The trailing twelve month revenue for BioMérieux is $4.66B.
-
Who are BioMérieux’s competitors?
Bio-Rad Laboratories, GSK, Hologic, Sartorius, and Novartis are some of the 14 competitors of BioMérieux.
-
What is BioMérieux’s annual earnings per share (EPS)?
BioMérieux’s EPS for 12 months was $4.58.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process